A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera

Basit Öğe Kaydı
dc.contributor.authorSerin, İstemi
dc.contributor.authorDoğu, Mehmet
dc.contributor.authorEkıncı, Omer
dc.contributor.authorÇağlıyan, Gülsüm Akgün
dc.contributor.authorBaştürk, Abdülkadir
dc.contributor.authorAras, Merih Reis
dc.contributor.authorDemircioğlu, Sinan
dc.date.accessioned2024-10-29T17:53:26Z
dc.date.available2024-10-29T17:53:26Z
dc.date.issued2023
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractIntroduction: Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV). Methods: A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: ?35%) by imaging and control of hematocrit levels (?45%) compared to baseline. Results: While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman’s rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman’s rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher’s exact test: p=0.033). Conclusion: This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups.
dc.identifier.doi10.4274/imj.galenos.2023.66742
dc.identifier.endpage125
dc.identifier.issn2619-9793
dc.identifier.issn2148-094X
dc.identifier.issue2en_US
dc.identifier.startpage120
dc.identifier.trdizinid1179468
dc.identifier.urihttps://doi.org/10.4274/imj.galenos.2023.66742
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1179468
dc.identifier.urihttps://hdl.handle.net/20.500.11776/13566
dc.identifier.volume24
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofİstanbul Medical Journal
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleA Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu